Dutch venture capital firm BioGeneration Ventures is looking to expand the portfolio of early-stage, human health-focused firms in its BGV III fund after securing €66m to invest. It has already invested in four companies – one German, three Dutch – and expects to invest in 15 in total. It has beaten its initial target for BGV III of €50m and expects to reach the maximum fund size of €75m by the end of 2017. This compares with its two previous funds of €17m in 2006 and €15m in 2012.
Bio Boost For Benelux As BioGeneration Ventures Beats Fund Target
Dutch life sciences venture capital firm BioGeneration Ventures has exceeded the €50m target in a third closing of its BGV III fund, raising €66m. It intends to focus its investments on firms in the Netherlands, Belgium, Luxembourg and Germany, and expects to secure further funds, reaching the maximum fund size of €75m by the end of 2017.
